We are a team of students driven by the belief that science should not end at discovery, but should find its way into real-world applications. At the beginning of our project, when we first started seriously considering the path toward commercialization, we took part in various events to better understand the essence of translating scientific research into practice - especially within the field of biotechnology.
The more time we spent exploring this area, the clearer it became that commercialization is neither obvious nor simple. Behind every innovative idea lies a complex process of validation, strategy, and adaptation to real market needs. As students working on our project within a university research institute, we quickly realized that bridging the gap between academic research and societal impact requires much more than strong science - it also demands entrepreneurial thinking, persistence, and the ability to learn from experts across disciplines.
Despite these challenges, we did not give up. On the contrary - we set ourselves the goal of shaping this project in such a way that commercialization would become its natural extension. Already at an early stage, we joined the incubation program of the Innovation Hub Foundation, the largest organization in Poland supporting startups. There, we learned how crucial it is to have a solid plan and, above all, a strong and committed team-the very foundation of every successful project.
Later, we had the opportunity to participate in the Cebioforum conference, the biggest biotechnology conference in Central and Eastern Europe. It was there that we engaged directly with representatives of biotech and health-tech startups from around the world, testing our ideas and confronting them with the experiences of others. These discussions with startup founders, technology professors, and innovation hub representatives further strengthened our conviction that we had chosen the right path. We realized that we are not alone in facing challenges, and even highly experienced teams often need to adjust their vision as their startups evolve.
At the same time, as representatives of the academic community, we want to set new standards in Poland for the commercialization of university research. We aim to show that applicability is a strength, not a weakness, and to demonstrate a clear path for transforming scientific discoveries into real-world solutions. Even at this early stage, we are confident that HepaSwitch has the potential to become a model project, bridging the gap between science and society while inspiring others to follow a similar path.
Especially as students, we want to demonstrate that age is not a barrier to innovation - that transformative ideas and world-changing solutions can emerge from young people when given the opportunity to take the first steps. We see our project as the initial step toward changing the reality of Polish universities in STEM fields, showing that students can lead the way in translating scientific discoveries into real-world impact.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults and one of the deadliest cancers worldwide. It is the 6th most common cancer overall and the 3rd leading cause of cancer-related deaths, with a five-year survival rate of only 18%. HCC most often develops in the context of chronic liver disease - particularly cirrhosis or fibrosis - caused by viral hepatitis (B, C, D), non-alcoholic steatohepatitis (NASH), alcoholic liver disease, or toxin exposure. In fact, up to 90% of patients with HCC also suffer from cirrhosis, which complicates treatment and reduces tolerance to existing therapies.
The disease is frequently diagnosed late: 40-60% of patients are identified at advanced stages (BCLC C/D), when curative options such as resection or transplantation are no longer possible. At this stage, current systemic therapies deliver only modest benefits, with median progression-free survival of 6.8 months - comparable to glioblastoma, one of the most aggressive cancers known.
If no effective interventions are introduced, the global incidence and mortality of liver cancer are projected to increase by more than 55% between 2020 and 2040. This growing health crisis highlights a clear unmet need:
there is strong demand for therapies that are not only effective but also selective and safe
capable of addressing the dual challenge of cancer progression and underlying liver dysfunction. Meeting this need offers a transformative opportunity to improve survival and quality of life for millions of patients worldwide.
That is why we are developing HepaSwitch, a breakthrough mRNA-based therapy designed specifically for hepatocellular carcinoma (HCC). HepaSwitch harnesses the precision of synthetic biology to remain inactive until it encounters RNA sequences unique to liver cancer cells. Upon detection, the toehold switch activates the translation of gasdermin, a protein that selectively induces cancer cell death, sparing healthy tissue. To ensure targeted action, the therapy is delivered via lipid nanoparticles (LNPs), which naturally accumulate in the liver and minimize off-target effects. By combining molecular specificity with organ-targeted delivery, HepaSwitch directly addresses the dual challenges of late-stage diagnosis and limited treatment safety in patients with compromised liver function. This innovative approach has the potential to redefine standards in HCC therapy, transforming scientific discovery into a real-world solution that saves lives.
Minimal Viable Product (MVP):
Our MVP, HepaSwitch, represents the first tangible step toward transforming our therapeutic concept into a functional product. It is a selective mRNA-based system designed to target hepatocellular carcinoma (HCC) cells while remaining inactive in healthy hepatocytes. The system relies on a toehold switch mechanism that recognizes specific HCC-associated mRNA markers and triggers the translation of gasdermin, a protein that induces pyroptosis - a highly immunogenic form of programmed cell death.
To validate our MVP, we encapsulated the therapeutic mRNA in lipid nanoparticles (LNPs) and tested its function in vitro using hepatocellular carcinoma cell lines alongside healthy hepatocyte controls.
We used a GFP reporter construct to confirm the specificity and selectivity of our toehold switch system. The selective activation of GFP in HCC cells demonstrated that the switch responds exclusively to the presence of target mRNA sequences, confirming the feasibility of cell-type-specific translation control.
Following validation of selectivity, we monitored pyroptotic markers - including IL-1β, IL-18, HMGB-1, ATP, and LDH release - to evaluate the therapeutic functionality of HepaSwitch. This step allowed us to assess whether the activation of our system leads to effective, immunogenic cell death specifically in HCC cells.
HepaSwitch MVP serves as a proof of concept for a new generation of selective mRNA therapeutics. By demonstrating specific activation and targeted cytotoxicity, this version provides critical data to guide future optimization and preclinical development.
Beyond HCC, our platform’s modular design allows for adaptation to other cancer types, simply by reprogramming the toehold switch to detect alternative disease-specific mRNA markers. This scalability positions HepaSwitch as a versatile therapeutic framework with potential applications across oncology.
From an entrepreneurial standpoint, our MVP acts as a technology validation milestone - bridging academic innovation with commercial viability. It establishes experimental evidence of selectivity, functionality, and delivery feasibility, which are crucial parameters for early-stage investment and partnership opportunities.
By validating HepaSwitch at the MVP stage, we lay the groundwork for future preclinical studies, licensing discussions, and startup incubation, moving our concept closer to real-world therapeutic impact.
We know how important it is to be well-prepared and to understand every element of our project, especially when addressing potential investors and future partners. That is why, alongside building the scientific foundation of HepaSwitch, we are also focusing on a clear development strategy. Our aim is not only to validate the technology in the lab but also to map the steps necessary for preclinical studies, regulatory pathways, and potential commercialization.
By approaching our project with this mindset, we ensure that HepaSwitch is developed not just as an academic proof-of-concept, but as a viable therapeutic innovation with real-world impact. This holistic preparation strengthens our credibility, demonstrates awareness of market and medical needs, and lays the groundwork for successful translation of our science into tangible solutions.
Our sales model is based on a business-to-business (B2B) strategy, with a clear pathway from early-stage research to market implementation. The development begins with preclinical and early clinical phases (Phase I/II), during which our team establishes the proof of concept, safety, and initial efficacy of the technology. At this stage, the project’s value is primarily scientific and innovative, creating a foundation for collaboration with larger industry players.
Once this foundation is established, the next step is to secure partnerships with pharmaceutical and biotechnology companies. These partners take over the advanced clinical development, regulatory processes, large-scale production, and global commercialization. By transferring responsibility for late-stage development to established industry leaders, we reduce the risks and costs associated with long-term product introduction while simultaneously accelerating the pathway to the market.
Revenue is generated through three complementary streams. The first consists of upfront payments provided by the industry partner at the moment of technology transfer or licensing. The second includes milestone payments tied to the successful achievement of predefined clinical or regulatory stages. Finally, long-term revenue is secured through royalties, typically in the range of 5-10% of product sales, ensuring sustainable financial returns.
This model allows us to combine academic innovation with industrial expertise, creating a realistic and scalable entrepreneurship pathway. By leveraging strategic partnerships, we can maximize the impact of our research, secure funding for future innovation, and contribute to the translation of synthetic biology into tangible medical solutions.
As we mentioned in the Human Practices section, we engaged in a series of discussions with medical professionals, oncologists, clinicians, and biotechnology experts to better understand the needs, expectations, and challenges faced by our potential customers. These consultations provided us with invaluable insights into the current limitations in hepatocellular carcinoma (HCC) diagnosis and treatment, enabling us to design our project with a clear clinical purpose and practical application. Through conversations with representatives from the biotech and pharmaceutical industries, we also gained a deeper understanding of commercialization pathways, regulatory frameworks, and market expectations. These insights allowed us to shape HepaSwitch into a solution that not only demonstrates strong scientific innovation but also aligns with the realities of healthcare systems and industry practices. Consultations with oncologists and clinicians were particularly important, as they helped us identify real clinical gaps, define potential use cases, and evaluate the feasibility of implementing our technology in medical settings. Altogether, these collaborations strengthened our understanding of our end users and reinforced our mission to develop a patient-centered, accessible, and sustainable biotechnology innovation.
Over the past few months, our team has successfully secured over €120,000 in combined funding through grants and fundraising initiatives. This accomplishment highlights both the innovative potential of our project and the trust we have built within the scientific and entrepreneurial communities. These funds have been crucial in advancing our research, supporting our entrepreneurial development, and enabling investment in key areas such as team training, experimental validation, and business strategy. Moreover, through this process we have also gained valuable experience in financial management and fund security, allowing us to ensure that our resources are used effectively and sustainably to maximize our project’s long-term impact.
As a synthetic biology project aiming to develop a targeted and personalized therapeutic switch for hepatocellular carcinoma (HCC), HepaSwitch fits perfectly into several national and international biotech funding and acceleration programs. Below is an overview of the most promising ones:
What it is:
SMART Pathway is a major funding instrument under Poland's European Funds for a Modern Economy (FENG). It supports R&D projects that include not only development, but also validation, commercialization and scaling.
Why HepaSwitch fits:
HepaSwitch involves a multidisciplinary innovation in synthetic biology and cancer therapeutics — making it an ideal candidate for a SMART Path project. The ability to design a custom therapeutic switch for liver cancer falls under the priority areas of personalized medicine and biotech.
What it offers:
Programs:
Thematic Programs (e.g., MedTech, Health-related calls)
Why HepaSwitch fits:
Our project is deeply rooted in scientific research and aims to bring a novel cancer therapeutic approach to clinical reality. It aligns with NCBR’s mission to translate high-tech solutions into the Polish and EU medical market.
What it offers:
What it is:
ABM provides dedicated grants for the development of new drugs, therapies, diagnostics, and clinical research infrastructure.
Why HepaSwitch fits:
HepaSwitch proposes a targeted gene circuit to be used in liver cancer cells—effectively a new class of gene therapy. This fits ABM’s calls for breakthrough medical technologies with potential to address oncological diseases.
What it offers:
What it is:
EIC supports the entire innovation journey—from deep-tech proof-of-concept to commercialization—through three main programs: Pathfinder, Transition, and Accelerator.
Why HepaSwitch fits:
What it offers:
What they offer collectively:
What it is:
An NCBR-backed soft-landing accelerator in Nevada and Silicon Valley for Polish deep-tech startups, including biotech.
Why HepaSwitch fits:
As a synthetic biology startup solving unmet needs in liver cancer treatment, we could use the NCBR-NAP program to prepare for U.S. trials, pitch to U.S. VCs, and build regulatory strategy.
What it offers:
Year 1: $581,391 (start) + $880,692 = $1.46M
Year 2: $880,692
Year 3: $880,692
TOTAL: $3,208,736
Main components: salaries ($1.76M), indirect costs ($608K), lab equipment ($374K), research materials ($267K)
Global HCC 2025: $2.2B; 2030: $3.3B (CAGR 8.8%)
Patients/yr: ~900k; Target 5%: 45k
At $1,000-2,000 per therapy → $45-90M/yr at 5% share
Conservative (2% market): Yr4-5: $15-25M → Yr6-7: $35-50M
Optimistic (5% market): Yr4-5: $45-60M → Yr6-7: $80-100M
EMA / FDA approvals, M&A checkpoints, competition response, commercialization ramp-up.
We have prepared a cost estimate outlining the projected expenditures for the next three years. This budget was developed based on the knowledge and guidance we gained through our collaboration with the University of Warsaw Incubator - Entrepreneurship Center, which has supported us at every stage of the project, particularly in the context of entrepreneurship. Their mentorship helped us understand the financial planning required to move a research project toward real-world implementation, ensuring that our budget reflects both scientific and operational needs for the coming years.
Recognizing the importance of anticipating potential challenges, we have placed strong emphasis on comprehensive risk analysis. Understanding possible obstacles at an early stage is essential for effective project management and long-term success. Therefore, we conducted a detailed risk assessment to ensure that our team is as well-prepared as possible to address and mitigate potential issues.
| Risk Description | Caused by and Consequences | Probability | Impact | Risk Rating | Controls / Mitigation Strategies |
|---|---|---|---|---|---|
| Inefficient toehold switch activation | Toehold switch may not efficiently recognize HCC-specific RNA sequences, leading to insufficient gasdermin expression and reduced therapeutic efficacy. | Medium | High | Severe | Optimize switch design through in-silico modeling and iterative testing; validate specificity using HCC vs. normal hepatocyte models. Collaborate with computational biology experts to refine RNA-RNA interaction prediction. |
| Uncontrolled gasdermin activation (off-target pyroptosis) | Off-target activation in non-cancerous hepatocytes may cause liver inflammation or cytotoxicity. | Low | Very High | Critical | Implement multi-layered regulatory control (dual-trigger design); perform in vitro safety testing with non-cancerous liver cells; integrate miRNA-based suppression in healthy tissue. |
| Inefficient LNP delivery to HCC cells | Lipid nanoparticles may not achieve optimal biodistribution or intracellular delivery efficiency in vivo. | Medium | High | Severe | Optimize LNP formulation for hepatic targeting; collaborate with formulation experts; perform biodistribution studies using fluorescent LNPs. |
| mRNA instability / degradation | mRNA therapeutic may degrade before reaching target cells, lowering efficacy. | High | Medium | Severe | Use optimized 5’ and 3’ UTRs; apply modified nucleosides (e.g., N1-methylpseudouridine); test storage stability and degradation kinetics. |
| Insufficient preclinical validation | Failure to meet preclinical endpoints (safety, efficacy) may delay investor interest and funding. | Medium | High | Severe | Partner with CROs experienced in oncology preclinical studies; establish clear TRL milestones; implement robust animal model validation. |
| Difficulty in IP protection and patentability | Overlapping patents or unclear ownership of switch or LNP technology could hinder commercialization. | Medium | High | Severe | Early IP consultation with tech transfer offices; file provisional patent as soon as unique sequences and constructs are validated; seek FTO (Freedom to Operate) analysis. |
| Regulatory uncertainty for mRNA-oncology therapies | mRNA-based targeted pyroptosis may face new or unclear regulatory pathways, delaying approval. | Medium | High | Severe | Engage regulatory consultants early; align preclinical protocols with EMA/FDA guidance for mRNA therapeutics; maintain transparent documentation. |
| Insufficient investor readiness / funding gap | High R&D and manufacturing costs (~4-5 mln PLN) might exceed available resources, delaying TRL advancement. | High | High | Critical | Prepare detailed financial roadmap and milestones; seek mixed funding (grants, VC, angel investors); leverage Innovation Hub Foundation and university incubator networks. |
| Team experience and scalability challenges | As a student-led team, limited experience in biotech entrepreneurship may slow growth and partnerships. | Medium | Medium | Moderate | Continue mentorship through incubators; form advisory board of biotech and regulatory experts; engage in accelerator programs. |
| Ethical / biosafety risks | Use of engineered mRNA and gene circuits could raise biosafety or ethical concerns. | Low | Medium | Moderate | Conduct full biosafety risk assessments; follow BSL-2 guidelines; engage with bioethics committees for transparency. |
| Sustainability and production scalability | Scaling biomanufacturing may generate environmental or cost inefficiencies. | Low | Medium | Moderate | Implement green chemistry practices; partner only with suppliers adhering to sustainability standards; monitor environmental KPIs. |
Summary
As part of our long-term vision for HepaSwitch, we are carefully exploring the possibility of patenting our biological molecule in the future. Understanding the regulatory landscape around biotechnology patents is crucial to ensure that our innovation is both secure and ethically managed.
To gain deeper insight into intellectual property protection and commercialization pathways, we held consultations with experts from the Center for Innovation of the Warsaw University of Technology and the Technology Transfer and Knowledge Center of the University of Warsaw. These discussions provided us with valuable guidance on how to navigate patent law, safeguard biotechnological projects, and structure potential commercialization efforts responsibly.
This experience not only expanded our knowledge of IP strategy but also reinforced our understanding of how complex and essential intellectual property protection is in the context of biotech innovation.
Goal
Define internal IP policy and assign responsibilities.Actions
Create an internal IP committee (PI, project lead, lab representative, TTO liaison). Establish procedures for invention reporting.Deliverables
Internal IP policy, invention disclosure template.Timeline
0-1 monthResponsible
Project lead + Technology Transfer Office (TTO)Goal
Secure clear proof of invention (what, who, when).Actions
Maintain dated lab notebooks, complete an Invention Disclosure Form with experiment details and contributors.Deliverables
Complete invention disclosure and supporting data.Timeline
Continuous (initial ASAP)Responsible
Research team + PIGoal
Assess novelty and commercial potential.Actions
Conduct patent and literature searches, analyze competitors and potential licensees.Deliverables
Prior art report, patentability recommendations.Timeline
0-2 months after disclosureResponsible
TTO + patent attorney or analystGoal
Protect know-how before filing.Actions
Sign NDAs and MTAs with external collaborators, define internal publication policies.Deliverables
Executed agreements, confidentiality logs.Timeline
Ongoing (pre-sharing)Responsible
Administrative team + TTOGoal
Identify potential infringement risks before commercialization.Actions
Review existing patents in target markets, assess licensing needs or design-arounds.Deliverables
FTO report with recommendations.Timeline
3-6 months before disclosure/preclinicalResponsible
Patent attorney + TTOGoal
Select the best protection path for each component.Actions
Compare patent and trade-secret advantages, considering cost, scope, and market timeline.Deliverables
IP protection strategy document listing key elements for patenting.Timeline
After FTO & prior art reviewResponsible
IP committee + legal advisorGoal
Secure priority date and enable further R&D.Actions
Prepare detailed description, data, and claims; collaborate with a patent attorney; file in selected jurisdiction.Deliverables
Application number and priority date.Timeline
Within 6 months of decisionResponsible
Patent attorney + TTOGoal
Prevent loss of novelty through premature disclosure.Actions
Implement “publication hold” procedures, align conferences, preprints, and social media communications with patent timelines.Deliverables
Publication calendar aligned with IP goals.Timeline
ContinuousResponsible
PI + communications lead + TTOGoal
Protect the invention in key global markets.Actions
Decide on PCT filing or direct national applications; select target jurisdictions (EU, US, JP, CN, etc.).Deliverables
PCT application or national filings; cost plan for maintenance.Timeline
Within 12 months of priorityResponsible
TTO + patent attorneyGoal
Generate experimental evidence to strengthen claims.Actions
Conduct preclinical studies and reproducibility tests to demonstrate specificity, selectivity, and therapeutic efficacy of the toehold switch system.Deliverables
Experimental reports, safety and efficacy data.Timeline
6-24 months (parallel to prosecution)Responsible
R&D teamGoal
Prepare for ethical and sustainable technology transfer.Actions
Develop IP pitch decks, licensing term sheets, business model (licensing, co-development, or tech sale).Deliverables
Investor materials, commercialization roadmap.Timeline
12-36 months (aligned with R&D)Responsible
TTO + business teamGoal
Manage the patent portfolio and defend IP rights.Actions
Pay maintenance fees, monitor competing patents, and prepare enforcement strategies if infringement occurs.Deliverables
Maintenance calendar, monitoring reports.Timeline
Ongoing (annual updates)Responsible
TTO + patent attorneyGoal
Expand IP coverage and protect incremental innovations.Actions
File follow-up applications for improvements (delivery systems, formulations, therapeutic combinations).Deliverables
Broader IP portfolio.Timeline
As new data emergesResponsible
R&D + patent attorneyGoal
Ensure legal, biosafety, and social responsibility compliance.Actions
Address Nagoya Protocol, biosafety, and ethical standards; design access-oriented licensing clauses for fair use.Deliverables
Compliance checklist, ethical access plan.Timeline
Parallel to commercialization planningResponsible
TTO + ethics officerAt HepaSwitch, we believe that every innovation carries both great potential and great responsibility. While developing our selective mRNA-based therapy for hepatocellular carcinoma (HCC), we carefully considered not only its medical and scientific benefits but also its possible long-term societal, ethical, and environmental impacts. Below, we summarize the positive outcomes our solution aims to achieve, as well as the potential challenges we remain committed to addressing responsibly.
The HepaSwitch project represents a meaningful step toward democratizing access to advanced medical diagnostics. By developing a synthetic biology-based system capable of detecting hepatocellular carcinoma (HCC) with high precision and affordability, the project directly addresses one of the world’s most urgent healthcare challenges — late cancer detection.
HepaSwitch can contribute to reducing global health inequalities by offering an accessible diagnostic solution suitable for low- and middle-income countries, where HCC incidence is highest and access to advanced testing remains limited. The platform’s cost-effectiveness allows for implementation in settings with limited infrastructure, making early diagnosis achievable for broader populations.
Beyond medical utility, the project promotes a culture of innovation and entrepreneurship among young scientists. It demonstrates that academic research can evolve into real-world applications, motivating students to engage in responsible science and problem-solving. This contributes to shaping a new generation of scientists aware of both scientific and social responsibilities.
By engaging with the public through educational campaigns, presentations, and collaboration with innovation hubs, the HepaSwitch team helps raise awareness about liver cancer prevention and the potential of synthetic biology in modern healthcare. This dialogue between science and society strengthens public trust in biotechnology and promotes science literacy.
Earlier and more accurate detection of liver cancer not only improves individual health outcomes but also decreases the socioeconomic burden of late-stage cancer treatment. This leads to a more sustainable healthcare system and greater productivity within affected populations.
While HepaSwitch offers significant social benefits, responsible innovation also requires recognizing potential risks and ethical challenges:
Even with efforts to make diagnostics affordable, disparities may persist between high-income and low-income healthcare systems. Implementation might initially favor regions with stronger biomedical infrastructure, potentially reinforcing existing inequalities.
As with any biomedical technology involving patient data and molecular diagnostics, ensuring ethical handling of genetic and medical information is crucial. Inadequate regulation or misuse could lead to privacy risks or discrimination in healthcare access.
The growing commercialization of academic projects might shift focus away from social good toward profit-driven priorities. It’s important that HepaSwitch maintains its commitment to accessibility and social responsibility as it progresses toward market implementation.
Below, we have attached the complete business plan, which is focused on outlining all the essential steps required for the development of HepaSwitch - from proof-of-concept, through preclinical and clinical validation, to potential market entry. This structured approach ensures that every stage is carefully considered, increasing the likelihood of successful translation from research to real-world application.
Business plan (PDF)In the following section, we present our pitch deck, which summarizes the essence of HepaSwitch in a clear and accessible way. The goal of this material is to explain not only what our solution is, but also why it matters - highlighting the problem we address, the innovation behind our approach, and the potential impact on patients and healthcare. By condensing the most important aspects of our project, the pitch deck serves as a tool to communicate with potential partners, mentors, and investors, showing the real-world value and future of our idea.
Pitch deck (PDF)We built our team by focusing on the unique skills and abilities of each member, with the primary goal of creating a truly interdisciplinary group. To better understand our strengths, weaknesses, and potential gaps, we made use of personality assessments such as the 16 Personalities test and the Gallup Strengths test. These tools provided us with valuable insights into individual traits and team dynamics, allowing us to maximize our collaboration and efficiency. In addition, we consulted with experts in team building and management, which helped us refine our approach. As a result, we established a well-balanced and effective team prepared to tackle the scientific and organizational challenges of the project.
The bar chart illustrates the distribution of 16 personality types within the team. It highlights which profiles are most and least common, helping to identify the team’s overall balance between analytical, creative, and organizational traits.
The heatmap presents correlations between personality traits. Positive values (red) indicate traits that tend to increase together, while negative values (blue) suggest contrasting behaviors. This helps uncover underlying relationships within the team’s mindset.
The radar chart shows the team’s average scores across the five personality dimensions: Energy, Mind, Nature, Tactics, and Identity. Peaks and valleys reveal dominant characteristics and potential areas of complementarity within the team.
The horizontal bar charts compare average trait scores for each personality dimension across different types. This helps visualize how specific traits vary between groups - for example, which types score higher in Energy or Tactics.
The heatmap presents correlations between personality traits. Positive values (red) indicate traits that tend to increase together, while negative values (blue) suggest contrasting behaviors. This helps uncover underlying relationships within the team’s mindset.
This pie chart visualizes the relative proportion of each personality type. It provides a quick overview of diversity across team members and shows how evenly personality types are represented.
This UMAP projection reduces multidimensional personality data into two dimensions, showing the relative similarity between team members. Clusters represent groups with similar personality structures, while outliers highlight unique individual perspectives.